No Prescription |
 |
 | ||
|
BONMAX Evista |
|
| ||
No Prescription » Prescription Drugs 3 » BONMAX Evista Raloxifene is used to prevent and treat bone loss (osteoporosis) in women after menopause. Maintaining strong bones by slowing bone loss helps to reduce the risk of fractures.Raloxifene may also lower the chance of getting a certain type of breast cancer (invasive) in women after menopause.This drug is different from hormones (including estrogens and progestins). It works by acting like estrogen (as a selective estrogen receptor modulator or SERM) in some parts of the body. Raloxifene helps to preserve bone mass but it does not affect the breast and uterus like estrogen or relieve symptoms of menopause such as hot flashes.This medication is not recommended for use in women before menopause. It should not be used in children.This medication should not be used to prevent heart disease.How to use Raloxifene OralTake this medication by mouth usually once a day with or without food or as directed by your doctor. Use this medication regularly to get the most benefit from it. Remember to use it at the same time each day.Be sure to include adequate amounts of calcium and vitamin D in your diet. Consult your doctor or pharmacist to see if you need to take calcium/vitamin D supplements. Buy BONMAX Evista and other Prescription Drugs 3 products online at Medstore. 330
About BONMAX Evista: Product Type: Prescription Drugs 3 BONMAX ( Evista Generic Raloxifene ) BONMAX (Evista Generic Raloxifene) Evista Generic Raloxifene 60mg 28 (4 x 7) Evista Generic Raloxifene BONMAX
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
